Kei Muro

Prof. Kei Muro

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
KMKei Muro
Kei Muro
HCHyun Cheol Chung
Hyun Cheol Chung
VSVeena Shankaran
Veena Shankaran
RGRavit Geva
Ravit Geva
DCDaniel Catenacci
Daniel Catenacci
YBYung-Jue Bang
Yung-Jue Bang

1 January 2019 in Annals of Oncology
Verified
Journal Article
Closed access
KMKei Muro
Kei Muro
ECE. Van Cutsem
E. Van Cutsem
YNY. Narita
Y. Narita
GPG. Pentheroudakis
G. Pentheroudakis
EBE. Baba
E. Baba
JDJ -Y Douillard
J -Y Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer (GC) was published in 2016, and covered the management and treatment of local, locoregional, locally advanced and metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and The Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic GC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic GC representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

1 September 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
KMKei Muro
Kei Muro
NBNarikazu Boku
Narikazu Boku
YSYasuhiro Shimada
Yasuhiro Shimada
ATAkihito Tsuji
Akihito Tsuji
SSShinichi Sameshima
Shinichi Sameshima
KSKenichi Sugihara
Kenichi Sugihara

1 January 2019 in Annals of Oncology
Verified
Journal Article
Closed access
KMKei Muro
Kei Muro
FLF. Lordick
F. Lordick
TTT. Tsushima
T. Tsushima
GPG. Pentheroudakis
G. Pentheroudakis
EBE. Baba
E. Baba
JDJ -Y Douillard
J -Y Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

1 January 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SKShinichi Kageyama
Shinichi Kageyama
HWHisashi Wada
Hisashi Wada
KMKei Muro
Kei Muro
YNYasumasa Niwa
Yasumasa Niwa
SUShugo Ueda
Shugo Ueda
HSHiroshi Shiku
Hiroshi Shiku
Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received the CHP-NY-ESO-1 complex vaccine, Drug code: IMF-001. Patients with advanced/metastatic esophageal cancer were enrolled and subcutaneously vaccinated with either 100 μg or 200 μg of NY-ESO-1 protein complexed with CHP. The primary endpoints were safety and humoral immune responses, and the secondary endpoint was clinical efficacy. A total of 25 patients were enrolled. Thirteen and twelve patients were repeatedly vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1 with a median of 8 or 9.5 doses, respectively. No serious adverse events related to the vaccine were observed. Three out of 13 patients in the 100-μg cohort and 7 out of 12 patients in the 200-μg cohort were positive for anti-NY-ESO-1 antibodies at baseline. In the 100-μg cohort, an antibody response was observed in 5 out of 10 pre-antibody-negatives patients, and the antibody levels were augmented in 2 pre-antibody-positive patients after vaccination. In the 200-μg cohort, all 5 pre-antibody-negative patients became seropositive, and the antibody level was amplified in all 7 pre-antibody-positive patients. No tumor shrinkage was observed. The patients who received 200 μg of CHP-NY-ESO-1 survived longer than patients receiving 100 μg of CHP-NY-ESO-1, even those who exhibited unresponsiveness to previous therapies or had higher tumor burdens. The safety and immunogenicity of CHP-NY-ESO-1 vaccine were confirmed. The 200 μg dose more efficiently induced immune responses and suggested better survival benefits. (Clinical trial registration number NCT01003808).

1 July 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
JCJosep María del Campo
Josep María del Campo
MBMichael Birrer
Michael Birrer
CDCraig Davis
Craig Davis
KFKeiichi Fujiwara
Keiichi Fujiwara
AGAshwin Gollerkeri
Ashwin Gollerkeri
AOAmit Oza
Amit Oza